| Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion RD Schreiber, LJ Old, MJ Smyth Science 331 (6024), 1565-1570, 2011 | 7592 | 2011 |
| Natural innate and adaptive immunity to cancer MD Vesely, MH Kershaw, RD Schreiber, MJ Smyth Annual review of immunology 29 (1), 235-271, 2011 | 2762 | 2011 |
| Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors F Ghiringhelli, L Apetoh, A Tesniere, L Aymeric, Y Ma, C Ortiz, ... Nature medicine 15 (10), 1170-1178, 2009 | 2128 | 2009 |
| Immune surveillance of tumors JB Swann, MJ Smyth The Journal of clinical investigation 117 (5), 1137-1146, 2007 | 2040 | 2007 |
| New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape D Mittal, MM Gubin, RD Schreiber, MJ Smyth Current opinion in immunology 27, 16-25, 2014 | 1939 | 2014 |
| Adaptive immunity maintains occult cancer in an equilibrium state CM Koebel, W Vermi, JB Swann, N Zerafa, SJ Rodig, LJ Old, MJ Smyth, ... Nature 450 (7171), 903-907, 2007 | 1826 | 2007 |
| Functional significance of the perforin/granzyme cell death pathway JA Trapani, MJ Smyth Nature Reviews Immunology 2 (10), 735-747, 2002 | 1750 | 2002 |
| Cancer immunoediting and resistance to T cell-based immunotherapy JS O’Donnell, MWL Teng, MJ Smyth Nature reviews Clinical oncology 16 (3), 151-167, 2019 | 1640 | 2019 |
| NKT cells: what's in a name? DI Godfrey, HR MacDonald, M Kronenberg, MJ Smyth, LV Kaer Nature Reviews Immunology 4 (3), 231-237, 2004 | 1582 | 2004 |
| Classifying cancers based on T-cell infiltration and PD-L1 MWL Teng, SF Ngiow, A Ribas, MJ Smyth Cancer research 75 (11), 2139-2145, 2015 | 1559 | 2015 |
| Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting H Matsushita, MD Vesely, DC Koboldt, CG Rickert, R Uppaluri, VJ Magrini, ... Nature 482 (7385), 400-404, 2012 | 1479 | 2012 |
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ... Annals of oncology 25 (8), 1544-1550, 2014 | 1407 | 2014 |
| Type I interferons in anticancer immunity L Zitvogel, L Galluzzi, O Kepp, MJ Smyth, G Kroemer Nature Reviews Immunology 15 (7), 405-414, 2015 | 1309 | 2015 |
| Translational biology of osteosarcoma M Kansara, MW Teng, MJ Smyth, DM Thomas Nature Reviews Cancer 14 (11), 722-735, 2014 | 1193 | 2014 |
| NKT cells: facts, functions and fallacies DI Godfrey, KJL Hammond, LD Poulton, MJ Smyth, AG Baxter Immunology today 21 (11), 573-583, 2000 | 1175 | 2000 |
| Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity MJ Smyth, GP Dunn, RD Schreiber Advances in immunology 90, 1-50, 2006 | 1150 | 2006 |
| Differential tumor surveillance by natural killer (NK) and NKT cells MJ Smyth, KYT Thia, SEA Street, E Cretney, JA Trapani, M Taniguchi, ... The Journal of experimental medicine 191 (4), 661-668, 2000 | 1147 | 2000 |
| Targeting natural killer cells in cancer immunotherapy C Guillerey, ND Huntington, MJ Smyth Nature immunology 17 (9), 1025-1036, 2016 | 1128 | 2016 |
| Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ... Nature medicine 20 (11), 1301-1309, 2014 | 1120 | 2014 |
| A fresh look at tumor immunosurveillance and immunotherapy MJ Smyth, DI Godfrey, JA Trapani Nature immunology 2 (4), 293-299, 2001 | 1093 | 2001 |